November 24, 2026

NIPRO CORPORATION

Gentuity Appoints Desmond Adler as President and Chief Executive Officer

Leadership transition positions Gentuity to accelerate innovation and advance its next stage of growth

SUDBURY, Mass., November 23, 2026 – Gentuity, a NIPRO company, today announced the appointment of Desmond Adler as President and Chief Executive Officer, effective immediately. Adler succeeds Gentuity founder and former CEO David Kolstad, who will continue to serve as Chairperson of the Board. The transition reflects Gentuity's evolution as the company advances its growth strategy and strengthens its position in intravascular imaging.

"We are pleased to announce the promotion of Desmond as Gentuity's President and CEO," said Aaron Nepper, Executive Officer, President, Vascular Business, NIPRO CORPORATION. "Gentuity is an important part of NIPRO's strategy to build a differentiated vascular portfolio, and intravascular imaging remains a key area of focus for us. NIPRO is committed to supporting Gentuity as it continues to expand its capabilities and reach more customers around the world under Desmond's leadership. We also thank David Kolstad for his vision and years of leadership since the founding, and we count on his continued guidance as Chairperson."

Adler joined Gentuity in 2022 and has held increasingly senior leadership responsibilities, most recently serving as President, where he led commercial strategy, business development, and corporate operations. Before joining Gentuity, Adler held leadership positions at Avedro, which was acquired by Glaukos, and LightLab Imaging, which was acquired by St. Jude Medical.

"Since joining Gentuity in 2022, Desmond has been a trusted partner and a strong leader in shaping our strategy, strengthening our organization, and advancing our mission," said Kolstad. "He combines deep cardiovascular industry expertise with exceptional leadership, operational discipline, and a steadfast commitment to our customers, employees, and stakeholders. As Gentuity enters its next stage of growth, I have complete confidence in his ability to lead the company forward."

"Gentuity has built a strong foundation, an exceptional team, and a compelling vision for the future," said Adler. "I am honored to lead the company at this important point in its journey. We will remain focused on delivering meaningful innovation for physicians and patients, supporting our customers, executing with excellence, and creating long-term value for our stakeholders. I look forward to working with our talented team and business partners as we continue to build and scale Gentuity."

Adler's appointment follows a series of leadership investments designed to strengthen Gentuity's operational capabilities and sharpen its focus on customers, employees, and long-term growth. Recent leadership appointments and promotions include:

- **Almog Adar**, Chief Financial Officer, formerly Chief Financial Officer of Lifeward.
- **Alex Yildizyan**, Executive Vice President, Enterprise Operations, leading product development, operations, and quality, regulatory, and clinical functions.
- **Adam Heroux**, Vice President, Quality, Regulatory, and Clinical Affairs.
- **Patricia Modzelewski**, Vice President, Human Resources.
- **Jason Rudy**, Vice President, Global Commercial Development.
- **John Kummailil, PhD**, Vice President, Operations.

As Chairperson, Kolstad will continue to provide strategic guidance to the company, supporting long-term corporate strategy, business development, investor engagement, and governance while working closely with the Board, Adler, and the Gentuity executive team.

With an experienced leadership team, a strong operational foundation, and a continued commitment to innovation, Gentuity is well positioned to execute its strategic priorities, advance its product portfolio, expand its global reach, and deliver long-term value to customers, employees, investors, and partners.

About Gentuity
Gentuity, a NIPRO company, is pioneering the next generation of intravascular imaging. Through high-frequency OCT (HF-OCT) and ultra-low-profile catheter technology, Gentuity provides interventional cardiologists with complete vessel visualization and real-time insights to help optimize PCI procedures for coronary artery disease.

About NIPRO CORPORATION
NIPRO is a global healthcare company committed to improving patient outcomes through medical technologies, pharmaceutical solutions, PharmaPackaging, and regenerative medicine. Guided by its promise of helping people live longer and better lives, NIPRO partners with healthcare professionals around the world to deliver safe, reliable, and practical solutions that advance patient care.

Media Contact
David Reese | Americas Marketing & Communications
DavidRe@nipromed.com